Following adults in China after a bleed inside the brain
Follows adults with bleeding in the brain to learn about their recovery.
Plain-language title generated from the registry record
Registry title: Chinese Multicenter Cohort Study of Intracerebral Hemorrhage
Key facts
- Where
- Changsha, ChinaSee the site
Where in China
- Xiangya Hospital Central South UniversityChangsha, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Xiangya Hospital of Central South University
- Trial code
- NCT07833410
- Record updated
- 22 September 2026
- Original description
Spontaneous intracerebral hemorrhage is a severe form of stroke associated with high mortality and long-term disability. The Chinese Multicenter Cohort Study of Intracerebral Hemorrhage (CASA) is a prospective observational patient registry designed to enroll approximately 10,000 adults with imaging-confirmed spontaneous intracerebral hemorrhage and 2,000 adult healthy controls at more than 30 hospitals in China. The study will collect standardized clinical, laboratory, neuroimaging, lifestyle, and treatment data together with ethically approved blood, urine, and other biospecimens. Participants with intracerebral hemorrhage will be followed at 3 months, 6 months, and annually for up to 10 years. The primary objective is to characterize and identify determinants of the full distribution of modified Rankin Scale scores at 90 days. Secondary objectives include evaluating 90-day unfavorable functional outcome defined as mRS 4-6, recurrent intracerebral hemorrhage and mortality, identifying clinical and molecular biomarkers, and developing and externally evaluating multimodal prognostic models. The study does not assign treatment; all clinical care is determined by treating clinicians.Read full original descriptionShow less
Chinese Multicenter Prospective Cohort Study of Intracerebral Hemorrhage
Spontaneous intracerebral hemorrhage is a severe form of stroke associated with high mortality and long-term disability. The Chinese Multicenter Cohort Study of Intracerebral Hemorrhage (CASA) is a prospective observational patient registry designed to enroll approximately 10,000 adults with imaging-confirmed spontaneous intracerebral hemorrhage and 2,000 adult healthy controls at more than 30 hospitals in China. The study will collect standardized clinical, laboratory, neuroimaging, lifestyle, and treatment data together with ethically approved blood, urine, and other biospecimens. Participants with intracerebral hemorrhage will be followed at 3 months, 6 months, and annually for up to 10 years. The primary objective is to characterize and identify determinants of the full distribution of modified Rankin Scale scores at 90 days. Secondary objectives include evaluating 90-day unfavorable functional outcome defined as mRS 4-6, recurrent intracerebral hemorrhage and mortality, identifying clinical and molecular biomarkers, and developing and externally evaluating multimodal prognostic models. The study does not assign treatment; all clinical care is determined by treating clinicians.
Inclusion: Age 18 years or older; Intracerebral hemorrhage confirmed by head computed tomography and/or magnetic resonance imaging; Hemorrhage located in a deep cerebral region, cerebral lobe, cerebellum, or brainstem; Presentation to a participating hospital within 30 days after symptom onset; Written informed consent and broad consent provided in accordance with the ethics-approved process; Age 18 years or older; Able to provide written informed consent; No known history of intracerebral hemorrhage.
Exclusion: Neurologic disease, particularly any prior intracerebral hemorrhage; Traumatic intracerebral hemorrhage; Secondary intracerebral hemorrhage attributed to an arteriovenous malformation, ruptured aneurysm, moyamoya disease, cavernous malformation, hematologic disorder, hemorrhagic tumor, vasculitis, cerebral venous thrombosis, hemorrhagic transformation of cerebral infarction, or other prespecified secondary cause; Mixed intracerebral hemorrhage involving multiple deep and lobar locations at onset; Severe psychiatric disease that precludes study procedures or follow-up; End-stage hepatic or renal failure; Autoimmune disease judged by the investigator to materially affect study objectives; Active malignant tumor; Any other condition that the investigator judges makes participation inappropriate; Malignant tumor; Any other condition that the investigator judges makes participation inappropriate; Pregnancy.